Skip to main content
Premium Trial:

Request an Annual Quote

Newly Public Rosetta Genomics Says Q4 R&D Rises 30 Percent; No Revenue Yet

NEW YORK (GenomeWeb News) — Rosetta Genomics today released its first earnings statement as a new public company, saying it generated no revenues in the fourth quarter, R&D spending increased 30 percentl, and net losses increased 16 percent.
 
R&D spending for the three months ended Dec. 31, 2006, increased to $1.3 million from $1 million in the year-ago period.
 
The company said net loss increased to $2.1 million from $1.8 million in the fourth quarter of 2005.
 
Rosetta, which went public last month, said it had around $5.2 million in cash and equivalents as of Dec. 31.
 
The company said it is collaborating with Isis pharmaceuticals for a micro-RNA-based therapeutic for liver cancer, and said it has agreements in place with Max-Planck-Innovation, the Rockefeller University and Johns Hopkins University.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.